Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report View Sample

Published: December 28, 2022 Report Code: GDGMDHC22465IDB-ST

Select Item

Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview

Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance.

The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Retinitis Pigmentosa and features dormant and discontinued projects.

Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Targets

The key targets in the Retinitis Pigmentosa pipeline drugs market are Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Nucleoredoxin Like Protein 1, and others. Rhodopsin has the highest number of products in development in the Retinitis Pigmentosa pipeline drugs market.

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Targets

Retinitis Pigmentosa Pipeline Drugs Market Analysis by TargetsFor more target insights into the Retinitis Pigmentosa pipeline drugs market, download a free report sample

Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Retinitis Pigmentosa pipeline drugs market are Usherin Activator, Rhodopsin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Nucleoredoxin Like Protein 1 Activator, and others. Usherin Activator leads the Retinitis Pigmentosa pipeline drugs market in terms of MoA.

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Mechanisms of Action

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Mechanisms of ActionFor more MoA insights into the Retinitis Pigmentosa pipeline drugs market, download a free report sample

Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Retinitis Pigmentosa pipeline drugs market are intravitreal, intraocular, parenteral, ophthalmic, and others. The intravitreal RoA has the highest number of Retinitis Pigmentosa drugs in development in 2022.

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Routes of Administration

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Routes of AdministrationFor more RoA insights into the Retinitis Pigmentosa pipeline drugs market, download a free report sample

Retinitis Pigmentosa Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Retinitis Pigmentosa pipeline drugs market are gene therapy, small molecule, cell therapy, antisense oligonucleotide, and others. Gene therapy leads the Retinitis Pigmentosa pipeline drugs market in terms of molecule type.

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Molecule Types

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Molecule TypesFor more molecule type insights into the Retinitis Pigmentosa drugs market, download a free report sample

Retinitis Pigmentosa Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Retinitis Pigmentosa pipeline drugs market are SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, and 4D Molecular Therapeutics Inc. SparingVision SAS has the largest number of Retinitis Pigmentosa drugs in development in 2022.

Retinitis Pigmentosa Pipeline Drugs Market Analysis by Companies

Retinitis Pigmentosa Pipeline Drugs Market Analysis by CompaniesTo know more about the leading Retinitis Pigmentosa pipeline drugs market players, download a free report sample

Retinitis Pigmentosa Pipeline Products Market Overview

Key Targets Rhodopsin, Usherin, X Linked Retinitis Pigmentosa GTPase Regulator, Nucleoredoxin Like Protein 1, and Others
Key Mechanisms of Action Usherin Activator, Rhodopsin Activator, X Linked Retinitis Pigmentosa GTPase Regulator Activator, Nucleoredoxin Like Protein 1 Activator, and Others
Key Routes of Administration Intravitreal, Intraocular, Parenteral, Ophthalmic, and Others
Key Molecule Type Gene Therapy, Small Molecule, Cell Therapy, Antisense Oligonucleotide, and Others
Leading Companies SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc, and Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa.

  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Retinitis Pigmentosa therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Retinitis Pigmentosa

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the Retinitis Pigmentosa pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

4D Molecular Therapeutics Inc
AbbVie Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Alpine Biotherapeutics Corp
Anida Pharma Inc
Ankar Pharma SL
Applied Genetic Technologies Corp
Astellas Pharma Inc
Bayon Therapeutics Inc
Beijing Chinagene Tech Co Ltd
Biogen Inc
Brighton Biotech Inc
Casebia Therapeutics LLP
CIRC Biosciences Inc
Coave Therapeutics
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
DTx Pharma Inc
Editas Medicine Inc
EmendoBio Inc
Endogena Therapeutics Inc
Epicrispr Biotechnologies Inc
EyePoint Pharmaceuticals Inc
Eyestem Research Pvt Ltd
Eyevensys SAS
GenSight Biologics SA
Graybug Vision Inc
Grupo Ferrer Internacional SA
ID Pharma Co Ltd
InFlectis BioScience SAS
IVERIC bio Inc
jCyte Inc
Kala Pharmaceuticals Inc
Kubota Vision Inc
Limnopharma SL
Lineage Cell Therapeutics Inc
Locanabio Inc
MeiraGTx Holdings Plc
MimeTech Srl
Mitochem Therapeutics, LLC
Nanoscope Therapeutics Inc
Nanovector srl
Navega Therapeutics Inc
Novartis AG
Ocugen Inc
OiDE OptoEye Inc
OliX Pharmaceuticals Inc
ONL Therapeutics Inc
Opsis Therapeutics LLC
OptiKira LLC
Perceive Biotherapeutics Inc
Profarma
Prolindox Inc
ProQR Therapeutics NV
PYC Therapeutics Ltd
Ray Therapeutics Inc
ReNeuron Group Plc
ResQ Biotech
Restore Vision Co Ltd
Ripple therapeutics Corp
Rznomics Inc
Saliogen Therapeutics Inc
SanBio Co Ltd
SparingVision SAS
Staidson BioPharma Inc
Sumitomo Pharma Co Ltd
SunRegen Healthcare AG
Suzhou Ugenex Therapeutics Ltd Co
Sylentis SAU
Variant
ViGeneron GmbH
Viridian Therapeutics Inc
Wave Life Sciences Ltd
Worphmed Srl

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinitis Pigmentosa (Retinitis) – Overview

Retinitis Pigmentosa (Retinitis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Retinitis Pigmentosa (Retinitis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinitis Pigmentosa (Retinitis) – Companies Involved in Therapeutics Development

Retinitis Pigmentosa (Retinitis) – Drug Profiles

Retinitis Pigmentosa (Retinitis) – Dormant Projects

Retinitis Pigmentosa (Retinitis) – Discontinued Products

Retinitis Pigmentosa (Retinitis) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Ophthalmology reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more